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Sinmmary The effect of intratumoral recombinant interferon y (rIFN-y) as adjuvant to open cytoreduction
and external irradiation of 60 Gy on survival in adults with a newly diagnosed high-grade cerebral glioma was
studied. The patients were randomised during surgery into the rIFN-y group (n = 14) or the control group
(n = 17), and the latter received a subcutaneous reservoir of rIFN-7 injections. Intratumoral rIFN-y was given
three times a week for 4 weeks until radiotherapy, escalating the dose from 5 gig to 50;Lg. Both groups
received external whole-brain irradiation of 40 Gy and a local boost of 20 Gy. After radiotherapy, rIFN-y was
continued with 50 iLg twice a week up to 9 weeks. The patients received no chemotherapy. Intratumoral
rIFN-7 was tolerated well with transient fever only. There were 12 glioblastomas (GBs) in the control group
and nine in the rIFN-7 group with completed irradiation. The patients were followed clinically and by
computerised tomography (CT) every third month until death. Tumour responses were seen in three
interferon-treated (one still alive 45 months after operation) and in two conventionally treated patients. The
progression of the tumour volumes on CT did not differ between the IFN-treated and control groups. There
were no differences in the survival times. Median survival of the rIFN-^-treated patients was 54 weeks (95%
CI 35-68) and of the control patients 55 weeks (95% CI 41-77). Intratumoral rIFN-y given in the study
doses does not seem to inhibit tumour growth or improve the prognosis of patients with high-grade glioma.
Glioblastomas (GBs) make up 35-75% of all primary brain
tumours (Kallio, 1988). Glioblastoma multiforme and ana-
plastic astrocytoma are the most common and the most
malignant. Malignant gliomas are treated surgically, usually
with radiotherapy, and sometimes also with chemotherapy
(Nazarro & Neuwelt, 1990), and these treatments prolong the
life of a patient but practically never completely eradicate the
tumour. Since the beginning of 1980s, interferons (IFNs)
have been used to treat malignant gliomas. Mainly m (IFN-a)
and P (IFN-P) have been tried (Nagai & Arai, 1982;
Takakura, 1987; Allen et al., 1991; Yung et al., 1991). Pro-
mising results have also been reported with -y-interferon
(IFN-y) (Mahaley et al., 1983).
Gliomas are immunosuppressive, and the defect is at least
partially attributable to impaired T-cell function (Roszman et
al., 1991). The rationale of rIFN-7 treatment of glioma is to
restore and enhance the local immune response against
glioma tissue by up-regulation of glioma-associated and
MHC antigens, and by recruitment and activation of
leucocytes. IFN-y may act antiproliferatively by unmasking
antigenic determinants on the glioma cells and by inducing
expression of receptors for tumour necrosis factor (TNF) on
cells specific for IFN-y (Woll & Crowther, 1991). rIFN-7 was
chosen for clinical study because IFN-'y is the strongest
inducer of la antigen, especially class II antigens (DRA
antigens), expression and is also less neurotoxic than IFN-e
or IFN-P, making high intracerebral doses possible. In addi-
tion, glioma patients may have reduced IFN-y production as
a result of reduced T-lymphocyte activity. This is of specific
importance as IFN-y is a potent activator of macrophages,
and the production of IFN-y is influenced by interleukin 2
(IL-2) (Lee & Bigner, 1985). In order to achieve sufficiently
high concentrations of rIFN-y in the tumour, rIFN-y was
administered locally into the tumour cavity.
In the present study rIFN-y was administered locally into
newly diagnosed malignant gliomas as adjuvant to open
cytoreduction and external irradiation of 60 Gy. We chose to
treat fresh tumours to exclude the confounding effects of
previous surgery, radiotherapy and chemotherapy. Local
injections of placebo in the control group were not ethically
acceptable.
Patets and methods
Objectives ofthe study
1. To ascertain the safety of rIFN-y administration into a
cavity of cerebral glioma.
2. To study the effect ofintratumoral rIFN-y as adjuvant to
open cytoreduction and external irradiation of 60 Gy on
tumour control in adults with a newly diagnosed high-
grade (III-IV) cerebral glioma.
Eligibility criteria
1. Previously untreated high-grade (III-IV) cerebral glioma.
2. Age between 18 and 75 years.
3. Karnofsky performance scale over 60: needing at most
occasional assistance.
4. No other previous or concurrent disease or serious con-
dition likely to interfere with the treatment or assessment
of the outcome.
5. Oral informed consent obtained. The study protocol was
approved by the ethical committee of the Helsinki
University Central Hospital.
Surger, and randomisation
The patients were enrolled to the study between February
1988 and February 1991 from the patients referred to the
Department of Neurosurgery, Helsinki University Central
Hospital. Preliminary inclusion was based on CT. Ran-
domisation took place during surgery by using numbered,
sealed envelopes containing information on the treatment to
be given. The supposed malignant glioma was first debulked
from inside. If the frozen sections suggested a malignant
glioma (grade III-IV), the patient was randomised before
closure of the skull to the control group or the rIFN-'y group.
Those of the rIFN-y group received a subcutaneous LeRoy
capsule with the tip of the catheter in the tumour cavity for
local rIFN-y administration. The final histological diagnosis
was made by a neuropathologist (A.P.) from paraffin sections
according to the WHO classification (Zuilch, 1979).
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Treatment schedule
The planned treatment schedule for the control group and
for the rIFN-y group is presented in Figure 1. After the
resection all patients received 1 week's post-operative
neurosurgical care. The injections of rIFN-y into the LeRoy
capsule were started on the seventh post-operative day, and
rIFN-y was administered three times a week for 4 weeks until
radiotherapy, escalating the dose from 5 lzg to 50 jig. rIFN-y
was not given during radiotherapy because of the possibility
of enhancing radiation damage, as reported for natural IFN-
a in lung cancer (Maasilta et al., 1992). The planned
radiotherapy was the same for all patients in both groups,
starting in the fourth or fifth post-operative week. A total of
60 Gy was delivered in 30 fractions each of 2 Gy, five times a
week, for either 6 or 9 weeks, depending on whether or not a
3 week pause was introduced. The first 20 fractions (40 Gy)
were delivered to whole brain, followed by ten fractions
(20 Gy) of local irradiation. The local irradiation was
delivered to the target volume, planned to be the 2 cm mar-
gin outside the tumour border. After radiotherapy, rIFN-y
was continued with a dose of 50ILg twice a week for up to 9
weeks. The patients received no chemotherapy. Steroids,
anticonvulsants and other medication were given according
to clinical needs.
Safety ofrIFN-y administration
rIFN-y was produced in Escherichia coli using gene tech-
nology by Boehringer Ingelheim. Symptoms and signs of
possible side-effects were checked clinically, by ECG, by
blood pressure and pulse rate (2 and 4 h after intratumoral
rIFN-y injections) and laboratory tests (complete blood
analysis, thrombocytes, creatinine, aminotransferases, potas-
sium, sodium, calcium, glucose, protein, serum and urine
osmolality).
Follow-up and imaging
The tumours were imaged with CIT before operation, before
radiotherapy, after radiotherapy, and every third month until
death. Magnetic resonance imaging (MRI) was performed
without contrast enhancement as the contrast medium was
not registered for general use in 1988. MRI was not used for
tumour volume measurement; instead, tumour volumes were
measured on contrast-enhand CIT scans by two radiologists
who did not know the treatment the patient had received.
The tumour volume was calulated by multiplying the three
largest diameters, perpendiular to each other, and by using a
spherical correction factor of a/6.
Tumour responses were considered complete if the volume
of the tumour did not increase at all, and partial if the
increase in volume was no greater than 25% in 6 months.
Statistical analysis
The cumulative survivals were computed using the product-
limit method, and the difference between the survivals of the
two groups was evaluated with the generalised Wilcoxon test
using the BMDP statistical software (Benedetti, 1990). The
confidence intervals (95% CI) for the median survivals were
calculated according to Brookmeyer and Crowley (1982).
Period
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dose (mg)
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The planned treatment schedule in the trial with rIFN-
Results
Randomisation
A total of 32 patients were randomised to receive open
cytoreduction plus external irradiation of60 Gy with or with-
out intratumoral rIFN-y. One patient in the rlFN-'y group
was excluded because his tumour proved to be a metastatic
adenocarcinoma: fresh-frozen sections had suggested a malig-
nant glioma. The control group consisted of 17 patients and
the rIFN-'y group consisted of 14 patients (Table 1). The
median ages were similar, 57 years (range 36-69) in the
control group and 59 years (range 18-71) in the rIFN-y
group. The control group consisted of 15 patients with glio-
blastomas (GBs) and two with anaplastic oligodendrogliomas
(AOs), and the rIFN-y group consisted of 11 patients with
GBs and three with anaplastic astrocytomas (AAs) (Table 1).
Valid study groups
In the control group the whole treatment schedule took 14
weeks: two patients with GB died before radiotherapy and in
one patient with GB radiotherapy was interrupted owing to
poor clinical condition (Table I). In the rIFN-'y group the
schedule took 24 weeks: two patients with GB died before
radiotherapy and two patients with GB died before post-
irradiation rIFN-y therapy. In addition, one patient with GB
did not receive the total post-irradiation rIFN-y dose because
his LeRoy capsule was removed because of suspicion of
infection, which was not confirmed. One patient with AA
obviously did not receive a total rIFN-y dose because of
subgaleal leakage of rIFN--y during injection. The valid study
groups thus included 14 control patients and eight rIFN-y
patients.
rIFN-y treatment
Intratumoral rIFN-y injections were given to 14 patients
(Table I). The patients tolerated the scheduled dosage well,
with only a slight increase in body temperature about 4h
after the injection. No signs of systemic or CNS toxicity were
seen, and the blood parameters showed no noticeable
changes. No change in pulse rate or blood pressure was seen.
Twnour response topost-radiotherapy rIFN-y
After radiotherapy some tumour responses were seen. One
rIFN-^-treated patient is still alive 45 months after the oper-
ation with complete tumour response until a recently detected
small recurrence (Figure 2). In two of eight patients receiving
the whole planed dose of rIFN-y the tumour volumes were
reduced after the rIFN-y treatment period, in one patient for
7 months and in the other one for 41 months. In the control
group the volume remained stable in three patients. In the
other patients the tumour grew relentlessly in spite of all
treatments. In the valid rIFN- group (n= 8) there were two
complete and one prtial responses (3/8). In the valid con-
ventional treatment group (n = 14), two complete responses
were seen, giving response rates of 37.5% and 14.3%. The
difference is not statistically significant.
Survival analysis
The median survival of all the patients was 46 weeks (95%
CI 35-55), but one patient is still alive 45 months after
operation. The median survivals of the rIFN-^-treated and
conventionally treated groups were 41 (95% CI 12-55)
weeks and 52 (95% CI 31-60) weeks, respectively, for all
patients (Figure 2), the difference being not statistically
significant (P
= 91). When analysing the survival of patients
who received the whole planned treatments, the valid study
groups, the median survival was 54 (95% CI 35-68) weeks
for the conventional group and 55 (95% CI 41-77) weeks
for the rIFN-- group. The total rIFN-y dose was 1.09-
1.55 mg. There was no significant difference (P = 0.35) in the
survival times of these groups either. When only the glioblas-
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Table I Characteristics of patients in different study groups
Treatment
rIFN-y rIFN-7 Conventional Conventional
all (n = 14) valid (n = 8) all (n = 17) valid (n = 14)
Mean age (years) 55.3 53.1 54.9 53.9
s.d. 9.5 7.5 13.6 9.7
Range 36-69 44-64 18-71 36-69
Men 5 2 9 8
Women 9 6 8 6
Histology
Glioblastoma 11 6 15 12
Anaplastic 3 2 -
astrocytoma (grade III)
Anaplastic oligo- - - 2 2
dendroglioma (grade III)
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cumulative survival of valid study groups (interferon, n = 8; con-
ventionaL, n = 14).
toma patients in the control group and in rIFN-y group are
compared, the following observations can be made:
1. All GB patients (I15 vs II): the median ages were 57 years
vs 62 years, and the median survival times were 46 weeks
vs 40 weeks respectively.
2. All GB patients receiving total irradiation (12 vs 9): 55
years vs 62 years and 53 weeks vs 41 weeks respectively.
3. All GB patients living for at least 24 weeks (the duration
of the rIFN--y schedule) in the control group (12 patients)
or receiving the total rIFN--y treatment (sixc patients): 55
years vs 50 years and 53 weeks and 60 weeks respectively.
Diussco
This is to our knowledge the first randomised study of
intratumoral rIFN--y in newly diagnosed high-grade glioma.
Treatment with the maintenance dose of 50ig rIFN-y1 was
well tolerated. The only side-effect was transient elevation of
body temperature 4h after injections, which signifies
diffusion of the injected rIFN-- outside the tumour cavity as
the temperature response is considerecl to be mediated by
the mid-brain. No signs of systemic or central nervous system
toxicity were seen. The 9 week treatment period was chosen
because it was considered to be long enough to demonstrate
any anti-tumour effect of rIFN-y. Although the whole treat-
ment schedule consisted of 30 punctures into the LeRoy
reservoir, there were few problems with the device. The
frequency of administration, 2-3 times a week, was chosen
because this schedule is widely used in other cancer studies.
Compared with local administration in studies with other
tumours such as mesothelioma and ovarian carcinoma, the
dose of rIFN-y chosen for this study was rather low. The
main reason for the low dose was safety.
Although 31 patients were randomised to receive either
rIFN-y or conventional treatment, only 22 (71%) patients
received the entire planned therapy, and in the rIFN--y group
only 8/14 (57%). Deterioration during the treatment of
malignant glioma is well known: in a Canadian study 68% of
the patients could start radiotherapy 3 weeks from diagnosis
and only 40% could start chemotherapy at 9 weeks (Winger
et al., 1989). This was a rIFN-y dose-defining study, and
tumour responses were looked for; tumour responses were
seen in both groups, and the tumour volume changes gave
the impression that increase in tumour growth took place
after rIFN-y injections were ceased. With a patient popula-
tion of 31 at the 5% significance level and 80% power level
only 25% or greater differences in 1 year survival rates could
have been detected (Machin & Campbell, 1987). As a conse-
quence we feel that, although small, our study did not miss
clinically truly relevant differences. Intratumoral rIFN-y
treatment in glioblastoma patients does not seem to improve
the survival of the patients, at least not with the low doses
used here. The median survival of our rIFN-y-treated
patients, 46 weeks from operation, is similar to that reported
in literature (Deutsch et al., 1989; Shapiro et al., 1992). The
patient population is representative of that generally par-
ticipating in clinical studies, and randomisation succeeded
rather well. There were no differences in the survival of the
rIFN-y-treated and conventionally treated patients. However,
the only long-term survivor did belong to the rIFN--y group.
Conclusions
Administration of rIFN-y into the cavity of cerebral glioma
is safe and well tolerated. There is no evidence that we
achieved the desired immunomodulation in the tumours and
the adjacent brain tissue. With the present dosage and
administration rIFN--y does not seem to increase survival
time in cerebral glioblastoma of adults. Whether higher doses
and longer administration would make a difference remains
to be determined. rIFN-y may have a role as adjuvant to
other antineoplastic agents in the treatment of glioma.
Referece
ALLEN. Jl, PACKER, R, BLEYER. A.. ZELTZER. P., PRADOS, M. &
NIRENBERG, A. (1991). Recombinant interferon beta: a phase
I-I1 trial in children with recurrent brain tumours. J. Clin.
Oncol., 9, 783-788.
BENEDE1TI, J. YUEN. K. & YOUNG. L. (1990). Life tables and
survivor functions. In BMDP Statistical Software Manual, Vol. 2,
Dixon, WJ. (ed) pp. 739-768. University of California Press:
Berkeley, CA.INTRATUMORAL IFN-y IN NEWLY DIAGNOSED GLIOBLASTOMA 141
BROOKMEYER. R. & CROWLEY. J. (1982). A confidence interval for
the median survival time. Biometrics. 38, 29-41.
DEUTSCH. M.. GREEN. S.B.. STRIKE. TA.. BURGER. P.C.. ROBERT-
SON. J.T.. SELKER, R.G.. SHAPIRO. W.R.. MEALEY. Jr. J. RAN-
SOHOFF. J.. PAOLETTIl. P.. SMITH. Jr. K.R.. ODOM. G.L.. BUNT.
W.E.. YOUNG. B.. ALEXANDER. Jr. E.. WALKER. M.D. & PISTEN-
MAA. D.A. (1989). Results of a randomized trial comparing
BCNU plus radiotherapy, streptozotocin plus radiotherapy, and
BCNU following misonidazole plus radiotherapy in the post-
operative treatment of malignant glioma. Int. J. Radiat. Oncol.
Biol. PhYs.. 16, 1389-1396.
KALLIO. M. (1988). The incidence of intracranial gliomas in southern
Finland. Acta Neurol. Scand., 78, 480-483.
LEE. Y. & BIGNER. DD. (1985). Aspects of immunobiology and
immunotherapy and uses of monoclonal antibodies and biologic
immune modifiers in human gliomas. Neurol. Clin., 3, 901-98.
MAASILTA. P.. HOLSTI. L.R.. HALME. M.. KIVISAARI. L.. CANTELL.
K. & MATTSON. K. (1992). Natural alpha-interferon in combina-
tion with hyperfractionated radiotherapy in the treatment of
non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys.. 23,
863-868.
MACHIN. D. & CAMPBELL. MJ. (1987). Statistical Tables for the
Design ofClinical Trials. p. 111. Blackwell Scientific Publications:
Oxford.
MAHALEY. Jr. M.S. & GILLESPIE. G.Y. (1983). New therapeutic ap-
proaches to treatment of malignant gliomas: chemotherapy and
immunotherapy. Clin. Neurosurg.. 31, 456-469.
NAGAI. M. & ARAI. T. (1984). Clinical effect of interferon in malig-
nant brain tumors. Neurosurg. Rev.. 7, 55-64.
NAZZARO. J.M. & NEUWELT. E.A. (1990). The role of surgery in the
management of supratentorial intermediate and high-grade astro-
cytomas in adults. J. Neurosurg., 73, 331-344.
ROSZMAN. T., ELLIOT, L. & BROOKS, W. (1991). Modulation of
T-cell function by gliomas. Immunol. Today, 12, 370-374.
SHAPIRO. W.R., GREEN, S.B.. BURGER, P.C.. SELKER, R.G.. VAN-
GILDER J.C.. ROBERTSON. J.T., MEALEY Jr. J.. RANSOHOFF, J.
& MAHALEY. Jr, M.S. (1992). A randomized comparison of intra-
arterial versus intravenous BCNIU, with or without intravenous
5-fluorouracil, for newly diagnosed patients with malignant
glioma. J. Neurosurg., 76, 772-781.
TAKAKURA. K. (1987). Effect of interferon on malignant glioma. In
Internationale Erfahrnwgen mit Naturlichem b-Interferon, von
Wild, K., Vilcek, J. & Takakura, K. (eds) pp. 27-38. W. Zuck-
schwerdt Verlag: Munchen.
WINGER, MJ.. MACDONALD. D.R.. SCHOLD. Jr. S.C. & CAIRN-
CROSS. J.G. (1989). Selection bias in clinical trials of anaplastic
glioma. Ann. Neurol., 26, 531-534.
WOOL. P.J. & CROWrHER. D. (1991). The interferons: their proper-
ties and clinical role - an over view. In Interferons: Mechanisms
of Action and Role in Cancer Therapy. Crowther, D. (ed.)
pp. 3-13. Springer Berlin.
YUNG, W.K.. PRADOS. M.. LEVIN. V.A.. FETELL. M.R. BENNETr. J..
MAHALEY Jr. M.S.. SALCMAN. M. & ETCUBANAS. E. (1991).
Intravenous recombinant interferon beta in patients with recur-
rent malignant gliomas: a phase I II study. J. Clin. Oncol., 9,
1945-1949.
ZULCH. KJ. (1979). Histological Typing of Tumours of the Central
Nervous Sistem. World Health Organization: Geneva.